FibroGen, Inc. (NASDAQ:FGEN) Director James A. Schoeneck Purchases 250,000 Shares of Stock

FibroGen, Inc. (NASDAQ:FGEN) Director James A. Schoeneck acquired 250,000 shares of the company’s stock in a transaction that occurred on Thursday, March 20th. The stock was acquired at an average price of $0.35 per share, with a total value of $87,500.00. Following the acquisition, the director now directly owns 323,722 shares of the company’s stock, valued at approximately $113,302.70. This represents a 339.11 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

FibroGen Stock Up 17.1 %

Shares of FibroGen stock opened at $0.37 on Tuesday. FibroGen, Inc. has a 52-week low of $0.18 and a 52-week high of $2.80. The company has a market capitalization of $37.24 million, a P/E ratio of -0.30 and a beta of 0.82. The company has a 50 day moving average of $0.48 and a 200 day moving average of $0.43.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The firm had revenue of $3.14 million for the quarter, compared to analysts’ expectations of $24.91 million. As a group, research analysts anticipate that FibroGen, Inc. will post -0.8 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC lifted its stake in FibroGen by 3.1% during the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after purchasing an additional 32,884 shares during the last quarter. Two Sigma Securities LLC purchased a new stake in shares of FibroGen during the 4th quarter worth approximately $27,000. FMR LLC lifted its position in shares of FibroGen by 21.8% during the 3rd quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 68,569 shares during the last quarter. XTX Topco Ltd boosted its holdings in shares of FibroGen by 423.8% in the 4th quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 77,693 shares in the last quarter. Finally, Velan Capital Investment Management LP purchased a new position in shares of FibroGen in the 4th quarter valued at $42,000. Hedge funds and other institutional investors own 72.71% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of FibroGen in a research note on Tuesday, March 18th. StockNews.com began coverage on FibroGen in a research note on Saturday. They set a “hold” rating for the company.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.